JWJulia Beata Woźniak

Julia Beata Woźniak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Beata Woźniak has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The MIND Diet and Cognitive Health in Older Adults: Clinical Evidence, Neuroprotective Mechanisms and Research Gaps—A Narrative Review

    by Helena Strzelka, Julia Beata Woźniak, Jakub Marcel Korowicki, Milena Maria Dziedzina, Anna Zyskowska, Marta Labon, Bartosz Seroczyński

    Background. The MIND diet combines elements of the Mediterranean and DASH dietary patterns and was developed to support cognitive health. Evidence includes observational, randomised and experimental research. Aim. This narrative review evaluated associations between MIND diet adherence and cognitive outcomes in older adults and compared observational and randomised findings. Methods. PubMed, MEDLINE and Google Scholar were searched through August 2026. Studies addressing cognitive performance, cognitive decline, mild cognitive impairment or dementia were included. Experimental studies were used to assess biological plausibility. Findings were synthesised descriptively. Results. Most observational studies associated greater adherence with better global cognition and memory, slower cognitive decline and lower risks of cognitive impairment and dementia. Experimental evidence supports vascular, metabolic, antioxidant, anti-inflammatory, amyloid-related and gut–brain mechanisms. The principal three-year randomised trial found no significant cognitive or neuroimaging advantage over an active control. Both groups received dietary counselling and caloric restriction and experienced weight loss, while the intervention may have been too short to detect long-term effects. Secondary analyses suggested possible differences according to obesity and achieved adherence, but were exploratory. Conclusions. The MIND diet is consistent with established cardiometabolic recommendations and can be a part of a broader healthy-ageing strategy. Its specific ability to prevent cognitive decline or dementia remains unconfirmed. Longer randomised trials are required.

  • Open Access

    Autonomic Function in Inflammatory Bowel Disease: A Narrative Review of Objective Assessment and Physiological Monitoring

    by Jakub Korowicki, Julia Beata Wozniak, Helena Strzelka, Milena Dziedzina, Bartosz Seroczyński, Marta Labon, Anna Zyskowska

    Introduction and purpose: Autonomic alterations may contribute to the physiological heterogeneity of inflammatory bowel disease (IBD). This review examines objective autonomic assessment in Crohn disease and ulcerative colitis, focusing on physiological phenotyping and longitudinal monitoring. Methods: This focused narrative review synthesizes 25 included studies. Evidence on heart rate variability (HRV), Holter monitoring, cardiovascular reflexes, orthostatic responses, baroreflex function, sudomotor testing, and wearable-derived signals was organized by modality and relationship with disease activity. Brief description of the state of knowledge: HRV was the most studied modality and was associated with clinical, biochemical, and endoscopic activity in selected cohorts. Autonomic alterations may persist during remission and do not consistently correspond to symptoms or inflammatory markers. Reduced HRV alone does not establish autonomic neuropathy. Multimodal testing assesses complementary physiological domains and may yield discordant findings. Wearables offer opportunities for repeated assessment alongside sleep and physical activity, while neuromodulation remains investigational. Heterogeneous protocols, small cohorts, and limited external validation constrain clinical interpretation. Conclusions: Objective autonomic assessment may complement established IBD evaluation in selected patients. The proposed Clinical Algorithm and Physiological Framework are hypothesis-generating and require prospective validation. Standardized multimodal protocols and longitudinal studies are needed. Current evidence does not support autonomic biomarkers as stand-alone tools for disease monitoring or exercise prescription.

  • Open Access

    BEYOND SYMPTOM CONTROL: ADHD PHARMACOTHERAPY AND REAL-WORLD RISK REDUCTION – A NARRATIVE REVIEW

    by Lena Głuszkiewicz, Sara Elżbieta Czubak, Michalina Weronika Nieścioruk, Dominika Julia Kozdroń, Jan Szafranek, Julia Beata Woźniak, Jakub Marcel Korowicki

    Background: ADHD is associated with substantial impairment and elevated risks of severe real-world adverse events across the lifespan (e.g., suicidal behavior, motor vehicle crashes, substance misuse, criminality, and premature mortality). While randomized trials establish short-term efficacy for symptom control, evaluating long-term real-world risk reduction requires synthesizing evidence from diverse observational and causal-inference designs. Aim: This narrative review synthesizes current evidence on the association between ADHD pharmacotherapy and major real-world functional outcomes, balancing behavioral risk reduction against potential long-term cardiovascular safety concerns. Methodology: We searched PubMed, Web of Science, Embase, and PsycINFO for studies on stimulant and non-stimulant treatments. Evidence from randomized trials, register-based studies, within-individual comparisons, and target-trial emulations was synthesized narratively, focusing on how study design affects causal inference. Results: ADHD pharmacotherapy is associated with lower rates of suicidal behavior, substance-related problems, transport accidents, criminal convictions, psychiatric hospitalizations, and premature mortality. Conversely, long-term cumulative exposure—particularly to stimulants—is linked to increasing cardiovascular risk, especially hypertension, with stronger associations at longer durations and higher doses. Conclusions: ADHD pharmacotherapy contributes to critical real-world risk reduction beyond core symptom control. Clinical decisions should balance these behavioral and survival benefits against potential long-term cardiovascular risks through ongoing safety monitoring and individualized benefit-risk assessments.

  • Open Access

    Current Therapeutic Strategies for Inflammatory Bowel Disease: A Narrative Review

    by Anna Zyskowska, Bartosz Seroczyński, Julia Beata Woźniak, Jakub Marcel Korowicki, Marta Labon, Milena Dziedzina, Wiktoria Karolina Nowak, Andrzej Gu, Helena Strzelka

    Background: Inflammatory bowel disease (IBD) is a chronic, relapsing disorder resulting from genetic, immune, microbial, and environmental factors. Therapeutic options have expanded from conventional drugs to biologic agents and targeted small molecules, enabling individualized management. Aim: This narrative review aimed to summarize current treatment strategies for IBD, focusing on conventional therapies, biologics, targeted small molecules, antibiotics, and surgery. Materials and Methods: A narrative literature review was conducted using PubMed, MEDLINE, Google Scholar, and the Journal of Education, Health and Sport (JEHS). Current clinical guidelines, European Medicines Agency (EMA) product information, clinical studies, systematic reviews, and meta-analyses were reviewed, with attention to indications, efficacy, and safety. Results: Biologic agents and targeted small molecules have broadened therapeutic options for moderate-to-severe IBD. Anti-TNF agents, vedolizumab, ustekinumab, selective IL-23 inhibitors, Janus kinase (JAK) inhibitors, and ozanimod act through different pathways and allow treatment to be adapted to disease phenotype, severity, and previous treatment exposure. Conventional therapies, including aminosalicylates, corticosteroids, thiopurines, and methotrexate, remain important in selected situations. Antibiotics retain a role in specific complications, while surgery remains essential in refractory disease and structural complications. Conclusions: Contemporary IBD management follows an individualized, treat-to-target approach aimed at symptom control, objective inflammatory control, mucosal healing, and prevention of long-term complications. Despite therapeutic advances, uncertainties remain regarding treatment sequencing, predictors of response, long-term safety, and access to advanced therapies. Further research is needed to optimize personalized strategies and improve long-term outcomes.

  • Open Access

    EXERCISE-INDUCED LARYNGEAL OBSTRUCTION IN ATHLETES: AN UNDERRECOGNIZED CAUSE OF EXERTIONAL DYSPNEA, DIAGNOSTIC CONFUSION WITH ASTHMA, AND IMPAIRED EXERCISE TOLERANCE - A NARRATIVE REVIEW

    by Sara Elżbieta Czubak, Michalina Weronika Nieścioruk, Dominika Julia Kozdroń, Lena Głuszkiewicz, Alia Echtay Yarbou, Rami Mallah, Jan Szafranek, Julia Beata Woźniak, Jakub Marcel Korowicki

    Background: Exertional dyspnea is a clinically relevant symptom in athletes, particularly during high-intensity exercise. Although asthma and exercise-induced bronchoconstriction are commonly considered in this context, exercise-induced laryngeal obstruction (EILO) is represents an important upper-airway cause of exertional breathlessness that may remain underdiagnosed. Its symptomatic overlap and possible coexistence with lower-airway disease may contribute to diagnostic confusion, ineffective treatment and impaired sport participation. Aim: The aim of this narrative review was to synthesize current evidence on EILO in athletes, with emphasis on clinical presentation, diagnostic confusion with asthma and exercise-induced bronchoconstriction, effects on exercise tolerance, and available diagnostic and therapeutic strategies. Methods: A targeted literature review of peer-reviewed publications concerning EILO, inducible laryngeal obstruction, exertional respiratory symptoms in athletes, asthma, exercise-induced bronchoconstriction, continuous laryngoscopy during exercise and treatment strategies was performed. Evidence was synthesized narratively and organized into clinically relevant thematic sections. Results: EILO is characterized by transient narrowing of the laryngeal airway during exercise, usually under conditions of high ventilatory demand. Symptoms typically occur during peak exercise and may include inspiratory dyspnea, throat tightness, noisy breathing or stridor. The available literature indicates that EILO is clinically relevant among adolescents and athletes, particularly in symptomatic and referral-based cohorts. Because symptoms may mimic or coexist with asthma and exercise-induced bronchoconstriction, objective assessment of both upper- and lower-airway function is often required. Continuous laryngoscopy during exercise remains the current diagnostic reference standard. Management is usually conservative and may include education, speech therapy, breathing retraining, physiotherapy and inspiratory muscle training, while surgery is reserved for selected severe supraglottic cases. Conclusions: EILO should be considered in athletes with persistent, unexplained or atypical exertional dyspnea, especially when symptoms are predominantly inspiratory, occur during peak exercise and respond inadequately to asthma-directed treatment. Early recognition and objective assessment may reduce diagnostic delay, limit ineffective management and support maintenance of exercise tolerance, training quality and sport participation.